Epigenomics Market Will Expand at 13.7% Growth by 2030


13 Jul 2023

Share : linkedin twitter facebook

The global epigenomics market is expected to grow at a compound annual growth rate of 13.7% from the year 2022 till the year 2030.

Epigenomics Market Size and Growth Rate From 2022 To 2030

The analysis of the changes that take place in the proteins that are DNA related in cells or the DNA I studied with the help of epigenomics. Epigenomics has its application in the disease of cancer and this disease will provide major growth opportunities for this market. Partnership between various companies and strategic collaborations for carrying out the clinical research will play a significant role in the growth of the market.

Regional Snapshots:

The region of North America has emerged as the leading market for epigenomics as a result of the rapid research and development programs that are carried out by the key market players existing in this particular part of the world. The existence of various healthcare amenities that are innovated in this region has helped the market to record a considerable revenue over the period of time. The growth of the market is attributed to the rapid developments that have been observed regarding the diagnostic processes. An increasing demand for advanced technologies and methods in the healthcare sector has boosted the market for epigenomics to a great extent which is expected to grow further in the future as well. A significant growth has been observed in the region of Asia Pacific as a result of the increasing disposable income that is available with the people. An increasing demand for high quality health care facilities has helped the market to introduce new technologies into the sector.

The rapidly increasing clinical demands of the potential patients is helping the market to record a considerable revenue over the period of time. The region of Europe has also emerged as a leading market for the growth of epigenomics due to the active participation of the government.

Epigenomics Market Report Scope:

Report Coverage Details
Growth Rate from 2022 to 2030 CAGR of 13.7%
Largest Market North America
Base Year 2022
Forecast Period 2022 To 2030
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Market Dynamics:

Drivers:

As the amount of funds received for the purpose of research in epigenomics has increased in the recent years many new products are launched in the market. increased use of the tricks that are epigenomics based for diagnosis purposes have also increased. The use of this technique for treating cancer is one of the major factors that will lead to the growth of the market. Growing demand for personalized medicine is expected to provide good opportunities for the growth of the market in the coming years.

The development programs and the drug discovery programs have increased recently as a large amount of investments are made in the field and these investments are made in order to focus on coming up with novel strategies in order to reverse the transcriptional abnormalities and the epigenetic abnormalities. druggable targets that are extremely common are the epigenetic targets and this class is expected to provide good opportunities for the growth of the market. There are some metabolic disorders, oncology disorders, neurology disorders and cardiovascular disorders in the targets.

Restraints:

Epigenomic data has limited application for toxicology. There is no clear and complete understanding for the epigenomic variability and this has reduced the knowledge on the risk assessment for the populations and types of tissues. There is a growing demand for new solutions in the market in order to make sure that proper understanding of the mechanisms in this field can be obtained. Less identification on the cell types and tissues is on other factor that will restrain the growth of the market in the coming years.

Opportunities:

The government of many nations are actively participating in providing advanced healthcare facilities to the people by conducting extensive research and development programs. Rapid acceptance to advanced health care facilities has also increased the demand for such technologies into the market. A huge number of people all over the world belong to the geriatric population which proved to be a major opportunity for the growth of the market. Many initiatives have been taken up by the government in the field of epigenomics which has provided the market with lucrative opportunities.

Challenges:

The high cost associated with the instruments that are applied in this sector has emerged as a major challenge for the growth of the market. A lack of skilled workforce emerges as a major challenge for the growth of the epigenomics market which is expected to hinder the growth during the forecast period. Lack of disposable income available with the people emerges as a major drawback for the growth of the market as it hinders the introduction of new technologies.

Report Highlights:

On the basis of the products the reagents segment will have the largest market share in the coming years. Histones, primers PCR reagents and antibodies are the common reagents. Introduction of new technologies has made it possible to analyze at cellular, protein and gene levels. Highest compound annual growth rate will be registered for the kits segment. To detect the epigenetic modifications biotechnology companies or engaged in manufacturing kits that can be ready to use. On the basis of the technology used in the market the DNA methylation technique is expected to generate maximum revenue in the coming years. Histone acetylation is another technology that will record significant growth in the coming years. It is involved in the procedures like chromatin transcription, chromatin dynamics, cell cycle progression, DNA replication, nuclear import, neuronal repression, DNA repair and gene silencing. the use of this technology in oncology will generate maximum revenue which is predicted to be about 70%. As the number of cases have increased across the world the need for this technology will also grow. Many new products are introduced in the market and same will be the case in the coming years. Highest compound annual growth rate will be registered for the non-oncology segment due to a large amount of research and development initiatives taken by the biopharmaceutical companies and private institutions.

Recent Developments:

  • In April 2021 - Eurofins genomics India which is a provider of genomic services and products is a leading company. This company has disclosed its introduction of SARS-CoV-2 full length genome sequencing.

Major Key Players:

  • Thermo Fisher Scientific (US)
  • Merck KGaA (Germany)
  • Illumina, Inc. (US)
  •  PacBio (US)
  • Abcam plc (UK)
  • Active Motif
  • Bio-Rad Laboratories (US)
  • Promega Corporation (US)
  • PerkinElmer (US)
  • Qiagen (Germany)
  • New England Biolabs (US)
  • Zymo Research Corporation (US)
  • Diagenode (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)

Market Segmentation:

By Product

  • Reagents
  • Kits
  • Chip sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA Sequencing Kit
  • Others
  • Instruments
  • Enzymes
  • Services

By Technology

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • Large non-coding RNA
  • MicroRNA Modification
  • Chromatin Structures

By Application

  • Oncology
  • Non oncology

Buy this Research Report@ https://www.precedenceresearch.com/checkout/2342

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

Related Reports